 |
Advances in Osteoporosis Management: Clinical Insights CME Mone Zaidi, MD, PhD, Program Chair/Moderator; Jonathan D. Adachi, MD, FRCPC; Steven T. Harris, MD, FACP Author Information and Disclosures Release Date: February 22, 2008; Valid for credit through February 22, 2009 | Physicians - maximum of 1.0 AMA PRA Category 1 Credit(s)™ for physicians | | This continuing medical education Webcast uses an innovative panel discussion format to review meta-analyses that address osteoporosis, bisphosphonate comparative dosing, and the bridging concept for extended dosing.
To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details Contents of This CME Activity Legal DisclaimerThe material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. Copyright © 2007 SCEPTERTM |
|
|
Learning Objectives Upon completion of this activity, participants will be able to: - Interpret secondary markers (eg, BMD, nonvertebral fractures) and apply them to daily clinical practice.
- Incorporate an understanding of the bridging concept into bisphosphonate therapy for patients with osteoporosis.
- Integrate meta-analytical data into the care of patients at risk for osteoporosis.
Authors and Disclosures Mone Zaidi, MD, PhD
Disclosure: Dr Zaidi serves on the speakers bureaus for Aventis, GlaxoSmithKline, Merck & Co., Inc., Novartis Corporation, Procter & Gamble Pharmaceuticals, and Roche.
Jonathan D. Adachi, MD, FRCPC
Disclosure: Dr Adachi has received grant and/or research support from Amgen, Eli Lilly and Company, GlaxoSmithKline, Merck & Co., Inc., Novartis Corporation, Pfizer Inc, Procter & Gamble Pharmaceuticals, and Roche. He also serves on the speakers bureaus for and is a consultant for Amgen, AstraZeneca LP, Eli Lilly and Company, GlaxoSmithKline, Merck & Co., Inc., Novartis Corporation, Pfizer Inc, Procter
& Gamble Pharmaceuticals, Roche, sanofi-aventis, and Servier. Steven T. Harris, MD, FACP
Disclosure: Dr Harris serves on the speakers bureaus for Eli Lilly and Company, GlaxoSmithKline, Merck & Co., Inc., Novartis Corporation, Procter & Gamble Pharmaceuticals, Roche, sanofi-aventis, and Wyeth Pharmaceuticals. Dr Harris is also a consultant for Amgen, Eli Lilly and Company, GlaxoSmithKline, Merck & Co.,
Inc., Novartis Corporation, Procter & Gamble Pharmaceuticals, Roche, sanofi-aventis, and Wyeth Pharmaceuticals. |
 |
SCEPTER is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians.
SCEPTER designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Contact This Provider
|
|
